Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
Cancer Medicine（2022）
摘要
The combination of anlotinib and PD-1/PD-L1 blockade has promising efficacy and safety as a second-line or subsequent therapy for SCLC.
更多查看译文
关键词
PD-1/PD-L1,anlotinib,antiangiogenics,small-cell lung cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要